Pricing

Novo Nordisk shares have staged a swift recovery in recent days, advancing nearly 12% over the past week…

Novo Nordisk’s shares have been hammered, losing roughly 46% over the past twelve months and trading at a…

New semaglutide kidney data boosts pipeline confidence, but CVS formulary changes and discounted Medicare pricing pressure margins, sending…

Novo Nordisk loses preferred CVS Caremark status for Wegovy as Eli Lilly gains parity; US pricing agreements squeeze…

Novo Nordisk partners with NOVI Health in Singapore, cuts US GLP-1 prices, and continues buybacks as stock dips…

Novo Nordisk faces key test at ADA with CagriSema Phase 3 data; Wegovy oral prescriptions surge, European reimbursement…

Novo Nordisk stock claws back from March low but faces pricing pressure in North America, reimbursement wins in…

Novo Nordisk tackles US pricing pressures with AI to cut clinical-to-filing time by two-thirds and a new UAE…

Novo Nordisk fights compounded competition with $149 oral Wegovy, and presents promising semaglutide data for MASH liver disease,…

Novo Nordisk’s Wegovy captures 19% of AI chatbot mentions for weight-loss, but adjusted Q1 revenue dropped 4% and…

Novo Nordisk repurchases billions in B-shares amid 44% stock drop, buoyed by strong Wegovy sales and a digital…

Novo Nordisk launches Phase 3 trial of Amycretin to prevent weight regain after diet, while a US drug…

Medicare Opens the Door for Novo Nordisk, but Pricing Squeeze Threatens to Slam It Shut